Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of acid-sensing GPCRs in Th17 cells and tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in a range of autoimmune conditions as well as in certain cancers. We are also more broadly interested in acid-sensing receptors in the immune system and their potential exploitation as targets for bringing about therapeutic benefit in a range of diseases.
Pathios employs a cutting edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios aims to rapidly deliver on the promise of novel therapeutic agents targeting these receptors. We combine a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.
Approx. 600 genes encoding GPCRs in the human genome
GPCRs are the largest single protein class targeted by marketed drugs
No approved drugs currently target any of the pH-sensing GPCRs on immune cells